Skip to content
Search

Latest Stories

AstraZeneca to take profit from Covid vaccine sales

BRITISH pharmaceutical giant AstraZeneca said Friday (12) it has begun to sell its Covid vaccine at a profit as the company posted a third-quarter loss on higher costs.

AstraZeneca, which has sold its vaccine at cost during the pandemic in contrast to rivals including US giant Pfizer, said it expects "to progressively transition... to modest profitability as new orders are received" in the current fourth quarter and beyond.


AstraZeneca posted a net loss of $1.65 billion for the third quarter compared with a profit after tax of around $650 million in the July-September period last year, a statement said.

AstraZeneca said it experienced higher costs in the current third quarter following its $39bn takeover of US biotech company Alexion, as well as increased research and development expenses across multiple programmes, including its Covid treatments. The group completed the Alexion takeover earlier this year.

Last month, the drugs company revealed positive results from a trial of a treatment for Covid-19 symptoms, which is being produced alongside its vaccine.

Made from a combination of two antibodies, the AZD7442 treatment had been undergoing final clinical trials to assess its safety and efficacy.

AstraZeneca said the limited profit contribution from the Covid vaccine in the current fourth quarter "is expected to offset costs relating to" AZD7442.

Chief executive Pascal Soriot told reporters that AstraZeneca had always planned to stop selling its Covid vaccine at cost.

But he stressed that the company wants "the vaccine to remain affordable".

The group added that revenue from its Covid vaccine, developed with the University of Oxford, totalled $2.22bn in the year to date following delivery of around 580 million doses worldwide.

Soriot said the company had "saved millions of hospitalisations" thanks to being the world's second-largest provider of Covid vaccines after Pfizer.

The drugs giant said total group revenue soared 50 per cent in the third quarter to almost $9.9 billion.

"AstraZeneca's scientific leadership continues to provide strong revenue growth and exceptional pipeline delivery... including our long-acting antibody combination showing promise in both prevention and treatment of Covid-19," Soriot said in the earnings statement.

Since taking the helm at AstraZeneca in 2012, Soriot has pushed the company into lucrative treatments such as cancer therapies, and the Alexion takeover gives it more heft in areas such as treating blood disorders.

More For You

Prudential to list Indian asset management venture

Prudential chief executive Anil Wadhwani

Prudential to list Indian asset management venture

INSURER Prudential plc announced that it is considering a partial listing of its stake in ICICI Prudential Asset Management, one of India's leading investment firms. The news sent Prudential's shares soaring by 5.8 per cent to close at 722p on the London Stock Exchange.

The FTSE 100 company currently holds a 49 per cent stake in the Indian joint venture, which market analysts estimate to be worth around £4 billion. ICICI Bank, which owns the remaining 51 per cent, has confirmed its intention to maintain its majority shareholding, emphasising its "long-term commitment" to the partnership that began in 1998, reported the Times.

Keep ReadingShow less
NatWest-Reuters

The bank has set a new performance target, aiming for a return on tangible equity of 15-16 per cent in 2025 and above 15 per cent by 2027. (Photo: Reuters)

What’s driving NatWest’s better-than-expected profit growth?

NATWEST reported higher-than-expected annual profit on Friday, supported by its growth strategy, improved productivity, and capital management efforts.

The bank, which once had assets worth 2.2 trillion pounds—more than twice the size of the British economy—has undergone years of restructuring to focus mainly on domestic consumer and mortgage lending.

Keep ReadingShow less
London business district
A general view shows the London's financial district from an office window in Canary Wharf. (Photo: Getty Images)

Economy grows 0.1 per cent in fourth quarter, defying expectations

THE UK economy expanded by 0.1 per cent in the final quarter of 2024, contrary to forecasts of a contraction, according to official data released on Thursday.

The growth, supported by a stronger-than-expected 0.4 per cent rise in December, offers some relief to chancellor Rachel Reeves as she navigates broader economic challenges.

Keep ReadingShow less
BP-Reuters

Fourth-quarter profit dropped 61 per cent compared to the previous year, marking BP’s weakest results since Q4 2020, when the pandemic reduced global oil demand. (Photo: Reuters)

BP reports lowest quarterly profit in four years, plans strategy reset

BP reported a quarterly profit of £943 million on Tuesday, falling short of expectations and marking its lowest in four years.

The company said it plans a "fundamental reset" of its strategy, days after reports that Elliott Management had taken a stake in the oil major.

Keep ReadingShow less
Shein-Reuters

Shein had aimed to go public in London in the first half of this year, subject to regulatory approvals in the UK and China. (Photo: Reuters)

Shein cuts valuation to £40 billion for London listing

SHEIN is preparing to lower its valuation to around £40 billion for a potential initial public offering (IPO) in London, according to three Reuters sources familiar with the matter.

This is nearly 25 per cent lower than the company's 2023 fundraising valuation as it faces increasing challenges.

Keep ReadingShow less